Literature DB >> 3508691

Prognostic utility of visual evoked potentials in term asphyxiated neonates.

H E Whyte1, M J Taylor, R Menzies, K C Chin, L J MacMillan.   

Abstract

The prognosis for term infants with birth asphyxia is variable and does not correlate well with the acute clinical state. Diagnostic tools such as electroencephalography or imaging techniques have not been satisfactory predictors of outcome. Visual evoked potentials (VEPs) have changed acutely in birth asphyxia and may provide information for long-term prognosis. We studied VEPs serially in 25 term infants with documented birth asphyxia. The VEPs were classified into three categories: normal, mildly abnormal, or severely abnormal, and then compared to each infant's acute clinical state and outcome at age six months. Eight of the nine infants with normal or mildly abnormal VEPs were normal when examined subsequently. All the patients with severely abnormal VEPs died, or suffered severe neurologic sequelae. The VEPs demonstrated good correlation with neurodevelopmental outcomes in infants with birth asphyxia and may be useful prognostically.

Entities:  

Mesh:

Year:  1986        PMID: 3508691     DOI: 10.1016/0887-8994(86)90051-2

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  Predictive value of early neuroimaging, pulsed Doppler and neurophysiology in full term infants with hypoxic-ischaemic encephalopathy.

Authors:  P Eken; M C Toet; F Groenendaal; L S de Vries
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-09       Impact factor: 5.747

2.  Flash visual evoked potentials at 2-year-old infants with different birth weights.

Authors:  Jing-Jing Feng; Ting-Xue Wang; Chen-Hao Yang; Wei-Ping Wang; Xiu Xu
Journal:  World J Pediatr       Date:  2010-05-21       Impact factor: 2.764

3.  Effect of sleep state on the flash visual evoked potential. A case study.

Authors:  A Shepherd; K Saunders; D McCulloch
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 1.854

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.